3 EFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS IN THE ASSURE STUDY: INTERIM RESULTS
2024 · Gastroenterology · 0 citations
https://doi.org/10.1016/s0016-5085(24)03986-6
S
Sarah Proehl
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
24
Papers
342
Citations
4
h-index
2
i10-index
Sarah Proehl is an academic researcher from Gilead Sciences (Canada). The author has contributed to research in topics: Liver Diseases and Immunity & Pediatric Hepatobiliary Diseases and Treatments & Gallbladder and Bile Duct Disorders. The author has an h-index of 4, co-authored 21 publications.
ORCID: 0009-0008-8255-3560Papers by this author
worksEFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS PREVIOUSLY TREATED WITH FIBRATES OR OBETICHOLIC ACID
2025 · Annals of Hepatology · 0 citations
https://doi.org/10.1016/j.aohep.2025.102051
Seladelpar Improves Cholestasis and Pruritus in Obeticholic Acid and Fibrate-experienced Patients With Primary Biliary Cholangitis
2026 · Clinical Gastroenterology and Hepatology · 0 citations
https://doi.org/10.1016/j.cgh.2026.01.011
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat